Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial
Robert D. Little(Hospital Universitario Fundación Jiménez Díaz), Miles Sparrow(Alfred Health), Peter De Cruz(The University of Melbourne), Kate D. Lynch(Royal Adelaide Hospital), G Walker(The University of Queensland), Desmond Chee(Monash Health), Jane M. Andrews(Health Net), Lena Thin(The University of Western Australia), Manjeet Sandhu(Monash Health), Mayur Garg(Eastern Health), Emily K. Wright(Brigham and Women's Hospital), Robert Gilmore(The University of Queensland), Patrick Hilley(Austin Health), Susan J. Connor(Liverpool Hospital), Georgina L. Hold(University of Aberdeen), Gregory Moore(Monash Medical Centre), Jonathan Segal(The Royal Melbourne Hospital), Alex Boussioutas(The Royal Melbourne Hospital), Mark G. Ward(The Alfred Hospital), Elizabeth Chow(Pediatrics and Genetics), Daniel Saitta(Western Health), Yoon K An(Mater Research), Robert V. Bryant(Queen Elizabeth Hospital), Jo McKenzie(The Alfred Hospital), Ashish Srinivasan(Eastern Health)
Cited by 5
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study
|The Lancet|2015|779
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers
|Journal of Medical Genetics|2015|567